InvestorsHub Logo
icon url

dewophile

01/12/22 6:14 PM

#241177 RE: ciotera #241176

I agree. The only thing I would add is that humira is still going to bring in meaningful sales for ABBV for a long time after it loses patent protection. Sometimes investors assume sales go zero and that’s just not the case.
icon url

DewDiligence

01/14/22 1:48 PM

#241197 RE: ciotera #241176

FDA approves Rinvoq for second-line atopic dermatitis:

https://finance.yahoo.com/news/u-fda-approves-rinvoq-upadacitinib-181000896.html

The approval includes both dose strengths (15mg and 30mg qD).
icon url

DewDiligence

01/10/23 10:00 AM

#245033 RE: ciotera #241176

ABBV now_expects Skyrizi/Rinvoq combined_2025_ sales_>=$17.5B—(up_from_prior_guidance_of_>=$15B):

https://finance.yahoo.com/news/abbvie-raises-sales-outlook-two-141249692.html

ABBV also expects peak combined annual sales of these two drugs will exceed $21B in 2027. All this despite the JAK limitation of Rinvoq to the second-line setting in most indications.

Comments?